Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma
NCT01170052Phase 2Withdrawn
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in mantle cell lymphoma (MCL), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Phase I: Dose-finding at 6 months and Phase II: Response Rate (Overall response rate, complete and partial response) at 6 months. Planned start May 2010; status: withdrawn.
02
Drugs
temsirolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01170052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170052.